Union européenne - français - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabète sucré, type 2 - les médicaments utilisés dans le diabète - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. triple thérapie de combinaison) en complément d'un régime alimentaire et l'exercice chez les patients insuffisamment contrôlés sur leur dose maximale tolérée de metformine et une sulphonylurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Union européenne - français - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabète sucré, type 2 - les médicaments utilisés dans le diabète - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. triple thérapie de combinaison) en complément d'un régime alimentaire et l'exercice chez les patients insuffisamment contrôlés sur leur dose maximale tolérée de metformine et une sulphonylurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Union européenne - français - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabète sucré, type 2 - les médicaments utilisés dans le diabète - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. triple thérapie de combinaison) en complément d'un régime alimentaire et l'exercice chez les patients insuffisamment contrôlés sur leur dose maximale tolérée de metformine et une sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Canada - français - Health Canada

dr reddy's laboratories ltd - sitagliptine (phosphate de stagliptine); chlorhydrate de metformine - comprimé - 50mg; 500mg - sitagliptine (phosphate de stagliptine) 50mg; chlorhydrate de metformine 500mg

Canada - français - Health Canada

dr reddy's laboratories ltd - sitagliptine (phosphate de stagliptine); chlorhydrate de metformine - comprimé - 50mg; 850mg - sitagliptine (phosphate de stagliptine) 50mg; chlorhydrate de metformine 850mg

Canada - français - Health Canada

dr reddy's laboratories ltd - sitagliptine (phosphate de stagliptine); chlorhydrate de metformine - comprimé - 50mg; 1000mg - sitagliptine (phosphate de stagliptine) 50mg; chlorhydrate de metformine 1000mg

Canada - français - Health Canada

apotex inc - sitagliptine (malate de sitagliptine); chlorhydrate de metformine - comprimé - 50mg; 500mg - sitagliptine (malate de sitagliptine) 50mg; chlorhydrate de metformine 500mg

Canada - français - Health Canada

apotex inc - sitagliptine (malate de sitagliptine); chlorhydrate de metformine - comprimé - 50mg; 850mg - sitagliptine (malate de sitagliptine) 50mg; chlorhydrate de metformine 850mg

Canada - français - Health Canada

apotex inc - sitagliptine (malate de sitagliptine); chlorhydrate de metformine - comprimé - 50mg; 1000mg - sitagliptine (malate de sitagliptine) 50mg; chlorhydrate de metformine 1000mg

Canada - français - Health Canada

pro doc limitee - sitagliptine (malate de sitagliptine); chlorhydrate de metformine - comprimé - 50mg; 500mg - sitagliptine (malate de sitagliptine) 50mg; chlorhydrate de metformine 500mg